Insulet Corporation (BIT:1PODD)
Italy · Delayed Price · Currency is EUR | Market Cap | 8.92B -40.3% |
| Revenue (ttm) | 2.52B +31.9% |
| Net Income | 262.62M -24.7% |
| EPS | 3.72 -22.7% |
| Shares Out | n/a |
| PE Ratio | 33.95 |
| Forward PE | 22.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 151 |
| Average Volume | 10 |
| Open | 149.70 |
| Previous Close | 144.50 |
| Day's Range | 131.50 - 149.70 |
| 52-Week Range | 131.50 - 306.90 |
| Beta | n/a |
| RSI | 22.22 |
| Earnings Date | May 6, 2026 |
About Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controll... [Read more]
Financial Performance
In 2025, Insulet's revenue was $2.71 billion, an increase of 30.73% compared to the previous year's $2.07 billion. Earnings were $247.10 million, a decrease of -40.93%.
Financial numbers in USD Financial StatementsNews
Insulet Earnings Call Transcript: Q1 2026
Q1 2026 delivered 30% constant currency revenue growth, margin expansion, and strong new customer starts, prompting a raised full-year revenue outlook to 21%-23%. Robust U.S. and international performance, innovation launches, and disciplined execution support confidence in sustained growth and profitability.
Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand
Insulet raised its annual revenue growth forecast on Wednesday after reporting better-than-expected quarterly results, driven by strong demand for its tubeless insulin pumps that eliminate the need ...
Insulet Reports First Quarter 2026 Results
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...
Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes
ACTON, Mass.--(BUSINESS WIRE)--Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes.
FDA Flags High-Risk Recall Of Insulet's Omnipod 5 Pods Over Insulin Delivery Concerns
The U.S. Food and Drug Administration (FDA) has classified a recall of Insulet Corporation's (NASDAQ:PODD) Omnipod 5 Pods as its most serious type, warning that continued use of affected devices could...
Insulet to Participate in BofA Securities 2026 Health Care Conference
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will prese...
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet Appoints Mike Panos as Chief Commercial Officer
ACTON, Mass.--(BUSINESS WIRE)--Insulet Appoints Mike Panos as Chief Commercial Officer.
PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $PODD--PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm.
Insulet recalls some insulin devices in US over leakage risk
Insulet has recalled specific batches of its insulin-delivery pods in the U.S. after finding a manufacturing defect that could stop diabetic users from getting their full dose of the blood sugar-reg...
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S.
Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes
ACTON, Mass.--(BUSINESS WIRE)--Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes.
Insulet to Present EVOLUTION 2 Results on Omnipod® Fully Closed-Loop System for Adults with Type 2 Diabetes at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
ACTON, Mass.--(BUSINESS WIRE)--Insulet to Present EVOLUTION 2 Results on Omnipod® Fully Closed-Loop System for Adults with Type 2 Diabetes at ATTD.
Diabetes-Focused Insulet Forecasts Strong 2026 Growth, Stock Soars
Insulet Corporation (NASDAQ: PODD) stock is trading higher on Wednesday after the company reported better-than-expected fourth-quarter earnings and 2026 guidance.
Insulet Earnings Call Transcript: Q4 2025
Delivered record revenue and customer growth in 2025, with strong expansion in both U.S. and international markets, especially in Type 2 diabetes. Guidance for 2026 anticipates continued double-digit growth, margin expansion, and robust innovation investment.
Insulet beats quarterly estimates on strong demand for wearable insulin pumps
Insulet reported better-than-expected fourth-quarter results on Wednesday, on the back of strong demand for its tubeless insulin pumps that eliminate the need for daily injections.
Insulet Reports Fourth Quarter and Full Year 2025 Results
ACTON, Mass.--(BUSINESS WIRE)--Insulet Reports Fourth Quarter and Full Year 2025 Results.
Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care
ACTON, Mass.--(BUSINESS WIRE)--Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care.
Is PODD A Better Bet Than ISRG Stock?
PODD is Intuitive Surgical's counterpart in the Health Care Equipment sector that has:
Insulet Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted sustained market leadership, robust financial growth, and a strong innovation pipeline, including major product launches through 2028. Strategic investments in R&D, manufacturing, and global expansion are expected to drive continued top-tier growth and market penetration.
Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will prese...
Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has announced ...